Clinical Trials
41 trialsAlternative-C
Ludwig-Maximilians - University of Munich
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
CBOT-OUD
Evon Medics LLC
FLMRD
Meir Medical Center
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
Ruijin Hospital
R2 in the Treatment of Follicular Lymphoma
Ruijin Hospital
ProT4
University College, London
Human Mesenchymal Stem Cells For Moderate and Severe Bronchopulmonary Dysplasia
Children's Hospital of Chongqing Medical University
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Clinica Universidad de Navarra, Universidad de Navarra
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
National Taiwan University Hospital
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Korea Cancer Center Hospital
Zevalin® First Line in Follicular Lymphoma
Charite University, Berlin, Germany
Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
The Korean Society of Pediatric Hematology Oncology
REAL07
Fondazione Italiana Linfomi - ETS
FLIDVAX2006
Clinica Universidad de Navarra, Universidad de Navarra
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
National Cancer Institute (NCI)
GOTEL-FL1LC
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
KLYMF
Oslo University Hospital